# Literature Matrix: Lithium and Alzheimer's Disease Research

## Overview

This matrix provides a comprehensive, systematic organization of all literature reviewed for this project, including government funding sources, trial registrations, and current study status.

---

## Part 1: Primary Research Studies

### Basic Science / Preclinical Studies

| Study | Year | Type | N | Funding | Key Finding | PMID |
| --- | --- | --- | --- | --- | --- | --- |
| Aron et al. (Nature) | 2025 | Basic + Translational | Human + Mouse | NIH/NIA, Ludwig Foundation, Glenn Foundation | Lithium is only metal reduced in MCI brains; orotate > carbonate | [40770094](https://pubmed.ncbi.nlm.nih.gov/40770094/) |

### Randomized Controlled Trials (RCTs)

| Study | Year | Registry | N | Duration | Population | Intervention | Funder | Result | PMID |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nunes et al. | 2013 | â€” | 40 | 15 mo | AD patients | Microdose Li carbonate (300 Âµg/day) | Not stated | âœ… Positive | [22746245](https://pubmed.ncbi.nlm.nih.gov/22746245/) |
| Forlenza et al. | 2019 | NCT01055392 | 61 | 4 years | Amnestic MCI | Li carbonate (0.25-0.5 mEq/L) | FAPESP (Brazil) | âœ… Positive | [30947755](https://pubmed.ncbi.nlm.nih.gov/30947755/) |
| Hampel et al. | 2009 | â€” | 71 | 10 wks | Mild AD | Li (0.5-0.8 mEq/L) | Not stated | âŒ Negative (cognitive); âœ… Biomarker | [19573486](https://pubmed.ncbi.nlm.nih.gov/19573486/) |
| Devanand et al. (Lit-AD) | 2022 | NCT02129348 | 80 | 12 wks | AD with agitation | Low-dose lithium | NIA (R01 AG041795) | âŒ Negative (agitation) | [34059401](https://pubmed.ncbi.nlm.nih.gov/34059401/) |
| Gildengers et al. (LATTICE) | 2025 | NCT03185208 | 80 | 2 years | MCI â‰¥60 years | Lithium vs placebo | NIH/NIA | ðŸ”„ Results pending | [40501510](https://pubmed.ncbi.nlm.nih.gov/40501510/) |

### Epidemiological Studies

| Study | Year | Type | N | Location | Exposure | Funder | Key Finding | PMID |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Kessing et al. | 2017 | Case-control | 807,384 | Denmark | Drinking water Li | Danish Council for Independent Research | 17% â†“ dementia at >15 Âµg/L | [28832877](https://pubmed.ncbi.nlm.nih.gov/28832877/) |
| Kessing et al. | 2008 | Registry cohort | ~5,000 | Denmark | Li treatment (bipolar) | Not stated | Only Li protected vs dementia | [18981345](https://pubmed.ncbi.nlm.nih.gov/18981345/) |
| Parker et al. | 2018 | Ecological | Population | USA | Groundwater Li | Not stated | Lower Li â†’ higher dementia rates | â€” |

---

## Part 2: Systematic Reviews & Meta-Analyses

| Study | Year | Studies Included | Total N | Methodology | Conclusion | Direction | PMID |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Matsunaga et al. | 2015 | 3 RCTs | 232 | Meta-analysis | SMD = -0.41 (p=0.04) | âœ… Favors Li | [26402004](https://pubmed.ncbi.nlm.nih.gov/26402004/) |
| Terao & Kodama | 2024 | 8 RCTs | 6,547 | Network meta-analysis | Li > aducanumab; safer than antibodies | âœ… Favors Li | [38253184](https://pubmed.ncbi.nlm.nih.gov/38253184/) |
| Shen et al. | 2024 | 264 references | Review | Comprehensive review | Li more effective than aducanumab | âœ… Favors Li | [39055498](https://pubmed.ncbi.nlm.nih.gov/39055498/) |
| Xiao et al. | 2026 | Systematic | Review | Systematic review | Inconsistent effects on amyloid; reduces p-tau | âš–ï¸ Mixed | [41260370](https://pubmed.ncbi.nlm.nih.gov/41260370/) |
| **Huang et al.** | **2024** | **8 studies** | **377,060** | **Meta-analysis** | **OR=0.94 (NS); No significant association** | **âŒ Null** | [38743015](https://pubmed.ncbi.nlm.nih.gov/38743015/) |

---

## Part 3: Government Funding Sources

### United States (NIH)

| Institute | Program | Grants Identified | Focus |
| --- | --- | --- | --- |
| National Institute on Aging (NIA) | Research Project Grants | R01 AG041795 (Lit-AD); Multiple R01s for LATTICE | Lithium for AD/MCI |
| NIA | Exploratory/Developmental | Multiple | Neuroprotection mechanisms |
| Ludwig Foundation | Private | Nature 2025 study | Basic science |
| Glenn Foundation for Medical Research | Private | Nature 2025 study | Aging research |
| Aging Mind Foundation | Private | Nature 2025 study | AD prevention |

### International

| Country | Agency | Studies Funded |
| --- | --- | --- |
| Brazil | FAPESP (SÃ£o Paulo Research Foundation) | Forlenza et al. 2019 (NCT01055392) |
| Denmark | Danish Council for Independent Research | Kessing drinking water study |
| Japan | Not specified | Terao et al. network meta-analysis |

### NIH-Authored Publications

| Publication | Date | Summary |
| --- | --- | --- |
| NIH Research Matters: "Lithium levels tied to Alzheimer's disease and dementia" | Sept 2025 | Official NIH summary of Nature 2025 findings |

---

## Part 4: Registered Clinical Trials (ClinicalTrials.gov)

### Alzheimer's/Dementia-Specific Trials

| NCT Number | Title | Status | Condition | N | Location | Results |
| --- | --- | --- | --- | --- | --- | --- |
| [NCT03185208](https://clinicaltrials.gov/study/NCT03185208) | LATTICE: Lithium As a Treatment to Prevent Impairment of Cognition in Elders | Completed | MCI | 80 | Pittsburgh, PA | âœ… Available |
| [NCT01055392](https://clinicaltrials.gov/study/NCT01055392) | Disease-modifying Properties of Lithium in the Neurobiology of AD | Unknown | MCI/AD | 61 | SÃ£o Paulo, Brazil | Published |
| [NCT02129348](https://clinicaltrials.gov/study/NCT02129348) | Treatment of Psychosis and Agitation in Alzheimer's Disease (Lit-AD) | Completed | AD (agitation) | 80 | Multi-site US | âœ… Available |
| [NCT00088387](https://clinicaltrials.gov/study/NCT00088387) | Effect of Lithium and Divalproex in Alzheimer's Disease | Completed | AD | â€” | Bethesda, MD (NIH) | â€” |
| [NCT02862210](https://clinicaltrials.gov/study/NCT02862210) | Low-Dose Lithium for Behavioral Symptoms in FTD | Completed | FTD | â€” | New York, NY | âœ… Available |

### Related Neurodegenerative Trials

| NCT Number | Title | Status | Condition | Location |
| --- | --- | --- | --- | --- |
| [NCT00703677](https://clinicaltrials.gov/study/NCT00703677) | Pilot Trial of Lithium in PSP or CBD | Completed | PSP/CBD | Multi-site US |
| [NCT00095355](https://clinicaltrials.gov/study/NCT00095355) | Effects of Lithium and Divalproex on BDNF in Huntington's | Completed | Huntington's | Bethesda, MD |

### Planned Trials (Not Yet Registered)

| Investigator | Institution | Intervention | Population | Status |
| --- | --- | --- | --- | --- |
| Dr. Bruce Yankner | Harvard Medical School | **Lithium orotate** (first human trial) | TBD | Announced Aug 2025; planning phase |

---

## Part 5: Evidence Quality Matrix

### GRADE Assessment

| Evidence Type | Studies | Quality | Limitations |
| --- | --- | --- | --- |
| Basic Science | Nature 2025 | â­â­â­â­â­ High | Single study (albeit comprehensive) |
| Animal Models | Nature 2025 + preclinical | â­â­â­â­â­ High | Mouse models may not translate |
| RCTs (positive) | 2 (Nunes, Forlenza) | â­â­â­ Moderate | Small N, single-site |
| RCTs (negative) | 2 (Hampel, Devanand) | â­â­â­ Moderate | Short duration (10-12 wks) |
| Meta-analyses (positive) | 2 (Matsunaga, Terao) | â­â­â­â­ Mod-High | Limited trials pooled |
| **Meta-analysis (null)** | 1 (Huang 2024) | â­â­â­â­ Mod-High | **Observational only; contradicts RCTs** |
| Epidemiological | 3 studies | â­â­â­â­ Mod-High | Cannot prove causation |

### Consistency Analysis

| Hypothesis | Basic Science | Animal | RCT | Epi | Meta | Overall |
| --- | --- | --- | --- | --- | --- | --- |
| Li is neuroprotective | âœ… | âœ… | âœ… | âœ… | âš–ï¸ | Strong |
| Li prevents AD | âœ… | âœ… | âœ… | âœ… | âš–ï¸ | Moderate |
| Li orotate > carbonate | âœ… | âœ… | â€” | â€” | â€” | Preliminary |
| Clinical recommendation | â€” | â€” | âŒ | â€” | â€” | Premature |

---

## Part 6: Gap Analysis

### Evidence Gaps

| Gap | Impact | Resolution Needed |
| --- | --- | --- |
| No lithium orotate human trials | Cannot validate Nature 2025 findings | Yankner planned trial |
| No Phase 3 RCTs | Insufficient for FDA approval | Large multi-site RCT |
| Contradicting meta-analysis | Weakens observational evidence | More RCTs needed |
| No dose-finding studies | Unknown optimal dose | PK/PD study |
| Limited elderly safety data | Risk assessment incomplete | Long-term safety study |

### Active Research Needs

| Priority | Research Question | Study Type Needed |
| --- | --- | --- |
| 1 | What is optimal lithium orotate dose for neuroprotection? | Phase 1/2 PK study |
| 2 | Does lithium orotate prevent conversion from MCI to AD? | Phase 2/3 RCT |
| 3 | Is biomarker response (p-tau217) predictive of clinical benefit? | Mechanistic RCT |
| 4 | What is long-term safety in non-psychiatric elderly? | Registry study |

---

## Part 7: Source Accessibility

| Source | Access Status | Alternative |
| --- | --- | --- |
| Nature 2025 | Open Access (PMC12443616) | PubMed |
| NIH Research Matters | Open Access | NIH website |
| Forlenza 2019 | Subscription | PubMed abstract |
| Matsunaga 2015 | Subscription | PubMed abstract |
| Terao 2024 | Subscription | PubMed abstract |
| Shen 2024 | Open Access (PMC11269163) | PubMed |
| Xiao 2026 | Open Access | PubMed |
| Huang 2024 | Subscription | PubMed abstract |
| LATTICE 2025 | Open Access (PMC12152361) | PubMed |
| Harvard Gazette | âŒ 404 Error | Replaced by PubMed sources |
| Psychology Today | âŒ 404 Error | Replaced by PubMed sources |
| Medscape | Paywall | Replaced by PubMed sources |

---

## Part 8: Timeline of Key Publications

```text
2008 â”€â”€â”€ Kessing bipolar registry (Denmark): Li protects vs dementia
    â”‚
2009 â”€â”€â”€ Hampel RCT: Negative (10 wks too short)
    â”‚
2013 â”€â”€â”€ Nunes microdose trial: Positive
    â”‚
2015 â”€â”€â”€ Matsunaga meta-analysis: Li cognitive benefit (p=0.04)
    â”‚
2017 â”€â”€â”€ Kessing drinking water study: Protective at >15 Âµg/L
    â”‚
2019 â”€â”€â”€ Forlenza 4-year RCT: Positive (cognitive + biomarkers)
    â”‚
2022 â”€â”€â”€ Devanand Lit-AD: Negative for agitation
    â”‚
2024 â”€â”¬â”€ Shen comprehensive review: Li mechanisms detailed
      â”œâ”€ Terao network meta-analysis: Li > aducanumab
      â””â”€ Huang meta-analysis: NULL RESULT (contradicting)
    â”‚
2025 â”€â”¬â”€ Nature (Aron/Yankner): Landmark mechanistic study
      â””â”€ LATTICE published: Results forthcoming
    â”‚
2026 â”€â”€â”€ Xiao systematic review: Mixed effects on amyloid
    â”‚
PLANNED â”€ Yankner lithium orotate trial (first human)
```

---

## Part 9: Funding Landscape Summary

### Total Identified Government Investment

| Category | Amount (Estimated) | Source |
| --- | --- | --- |
| NIH/NIA direct grants | >$5M | R01s for LATTICE, Lit-AD |
| NIH intramural research | Unknown | Studies at NIH Clinical Center |
| International (FAPESP, Denmark) | >$1M | Forlenza, Kessing studies |
| Private foundations | >$2M | Ludwig, Glenn, Aging Mind |

### Current Funding Gaps

- **No current NIH funding for lithium orotate trials**
- **No industry sponsorship** (lithium is generic, no patent protection)
- **Limited FDA pathway** unclear for repositioning

---

## Summary Statistics

| Metric | Count |
| --- | --- |
| Total peer-reviewed sources | 13 |
| Randomized controlled trials | 5 |
| Meta-analyses | 3 |
| Systematic reviews | 2 |
| Epidemiological studies | 3 |
| Registered clinical trials | 7+ |
| Government-funded studies | 6+ |
| Sources with positive findings | 10 |
| Sources with null/negative findings | 3 |
| Currently recruiting trials | 0 |
| **Direction of evidence** | **Predominantly supportive, with notable contradictions** |

---

**Last Updated:** February 5, 2026
